Digital health company, NeurodigitX reported on Wednesday the launch of Plastic Health platform, which allows a powerful mainstream bloodless assessment of inflammation levels in the current COVID-19 pandemic to enhance vaccine immunization strategies.
The company reportedly collects HRV, respiratory and cognitive data with the Plastic Egg, a biosensor and breathing-based game controller and Plastic mobile games guiding user's breath to measure inflammation accurately. Repeated gameplay allows profiling of slowly evolving (stress, chronic disease) and rapid changes (virus exposure, immunization) in inflammation status.
According to the company, it provides the only protocol-controlled, high-resolution, longitudinal, individualized routine measure of HRV and brain plasticity to closely track inflammation status. The Plastic Health reveals a draining of plasticity reserve, reflecting inflammation changes.
Nearly 50,000 scientific studies have been released on HRV (Heart Rate Variability), which affords a noninvasive assessment of inflammation of brain and bodily function. The company's Plastic Health combines individualized assessment and the heatmapping of public health. COVID-19 infection shows sudden inflammation change, further altered by the negative impact of cumulative stress.
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
AFYREN ingredient enables global launch of natural propionic acid skincare product
Merck reports positive Phase 2b results for tulisokibart in hidradenitis suppurativa
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
Ascletis reports positive results from ASC50 clinical study for treatment of plaque psoriasis
XtalPi submits US FDA IND application for KQTD-126 in chronic intestinal pain
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA